Doctor with patient. Image credit: Canva
Cancers of the female reproductive organs often come back after treatment. A drug called sacituzumab govitecan (SG) has been approved for use in other types of cancers. Researchers want to see if SG can also help people with ovarian, endometrial or cervical cancers.
A clinical trial led by Jung-Min Lee, M.D., Senior Investigator in the Women’s Malignancies Branch, is researching SG for adults with ovarian, endometrial or cervical cancers.
The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for medical care received at the Clinical Center.
For more information, please contact the NCI Cancer Information Service at 1-888-624-1937 or nciinfo@mail.nih.gov
Clinicaltrials.gov identifier: NCT06865677
NCI Protocol ID: IRB002068
Official Title: Phase II Pilot Study of Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.
